U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
NEW YORK, April 24, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Lion Biotechnologies, Inc. (NASDAQ:LBIO) who purchased shares between November 14, 2013 and April 10, 2017. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) through its former CEO Manish Singh, Lion was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites, as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
Shareholders have until June 13, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/lion-biotechnologies-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
